SynBioBeta Speaker

Geoff Hamilton

Ansa Biotechnologies

Chief Business & CFO

Geoff Hamilton is the Chief Business and Chief Financial Officer of Ansa Biotechnologies, a leading provider of gene synthesis products powering the next era of medicines and engineered biology. Geoff has a 24 year career in the industry spanning life science tools, genomics, and therapeutics. Geoff has been a leader in developing and launching revolutionary technologies in next-generation sequencing and applying gene and cell engineering tools to develop breakthrough therapeutics. Prior to joining Ansa, Geoff was the cofounder and CEO of Stemson Therapeutics, a cell therapy company developing regenerative treatments for skin diseases and hair loss conditions. Prior to founding Stemson, he spent six years at Illumina where he held leadership positions in product commercialization, clinical marketing, sequencing application strategy, and product portfolio management. Before Illumina, Geoff spent a decade at Life Technologies, a leading provider of tools, reagents, and analytical instruments before it was acquired by ThermoFisher Scientific. At Life Tech, he held a number of finance, marketing, commercial, and acquisition leadership roles.

Sessions Featuring

Geoff

This Year

Breakout Session

•

3:30 PM

-

4:15 PM

Human Health

Skip the Assembly, Go Straight to Your Next Breakthrough: How Innovative DNA Synthesis Is Changing What's Possible in Biopharma

The synthetic DNA field has entered an era of rapid innovation that is giving biopharma scientists new options when deciding whether to build or buy long and complex DNA. Previously hard-to-source DNA constructs are now readily available with an unprecedented guarantee for on-time shipping, eliminating procurement delays and empowering researchers to push the boundaries of synthetic biology. In this session, leading scientists will discuss how these advances are expanding design possibilities, accelerating design–build–test–learn cycles, and paving the way for the next wave of precision biotherapeutics.

Featuring

Christopher Vakulskas

Integrated DNA Technologies

Sr. Dir. of Enzyme Dev.

Colin Harvey

Hexagon Bio

Co-founder & VP, Early Discovery

Derek Smith

Gilead Sciences

Principal Scientist

Geoff Hamilton

Ansa Biotechnologies

Chief Business & CFO

Breakout Session

•

3:30 PM

-

4:15 PM

Human Health

Skip the Assembly, Go Straight to Your Next Breakthrough: How Innovative DNA Synthesis Is Changing What's Possible in Biopharma

The synthetic DNA field has entered an era of rapid innovation that is giving biopharma scientists new options when deciding whether to build or buy long and complex DNA. Previously hard-to-source DNA constructs are now readily available with an unprecedented guarantee for on-time shipping, eliminating procurement delays and empowering researchers to push the boundaries of synthetic biology. In this session, leading scientists will discuss how these advances are expanding design possibilities, accelerating design–build–test–learn cycles, and paving the way for the next wave of precision biotherapeutics.

Featuring

Christopher Vakulskas

Integrated DNA Technologies

Sr. Dir. of Enzyme Dev.

Colin Harvey

Hexagon Bio

Co-founder & VP, Early Discovery

Derek Smith

Gilead Sciences

Principal Scientist

Geoff Hamilton

Ansa Biotechnologies

Chief Business & CFO

Previous Speakers Include